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ImmunohistochemistrySummary Tumors of peripheral nerve are largely neuroectodermal in nature and derived from 2 elements
of nerve, Schwann or perineurial cells. In contrast, mesenchymal tumors affecting peripheral nerve are rare
and are derived mainly from epineurial connective tissue. The spectrum of the latter is broad and includes
lipoma, vascular neoplasms, hematopoietic tumors, and even meningioma. Of malignant peripheral nerve
neoplasms, the vast majority are primary peripheral nerve sheath tumors. Malignancies of mesenchymal
type are much less common. To date, only 12 cases of synovial sarcoma of nerve have been described.
Whereas in the past, parallels were drawn between synovial sarcoma and malignant glandular
schwannoma, an uncommon form of malignant peripheral nerve sheath tumor, molecular genetics have
since clarified the distinction. Herein, we report 10 additional examples of molecularly confirmed synovial
sarcoma, all arising within minor or major nerves. Affecting 7 female and 3 male patients, 4 tumors
occurred in pediatric patients. Clinically and radiologically, most lesions were initially thought to be
benign nerve sheath tumors. On reinterpretation of imaging, they were considered indeterminate in nature
with some features suspicious for malignancy. Synovial sarcoma of nerve, albeit rare, seems to behave in a
manner similar to its more common, soft tissue counterpart. Those affecting nerve have a variable
prognosis. Definitive recommendations regarding surgery and adjuvant therapies await additional reports
and long-term follow-up. The literature is reviewed and a meta-analysis is performed with respect to
clinicopathologic features versus outcome.
© 2011 Published by Elsevier Inc.1. Introduction cells, most are represented by schwannoma and neurofi-
broma. Only in recent years have the 2 variants ofThe vast majority of peripheral nerve tumors are
neuroectodermal in nature. Derived mainly from Schwann⁎ Corresponding author. Department of Pathology and Laboratory
edicine, Mayo Clinic, Rochester, MN 55905, USA.
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oi:10.1016/j.humpath.2010.08.019perineurioma come to be recognized, a soft tissue form
unassociated with nerve [1] and subsequently the intra-
neural variety involving multiple fascicles and exhibiting
pseudo-onion bulb formation, a highly distinctive histologic
feature [2]. Mesenchymal tumors and tumor-like lesions are
rare and comprise a wide variety of benign and malignant
soft tissue tumors [3,4].
569Synovial sarcoma of nerveSynovial sarcoma is a distinctly rare primary tumor
of nerve. Only 12 examples have been described to date
[5-15]. This may not only reflect its true rarity in this
anatomical location but may also reflect the natural
tendency of pathologists to diagnose as “malignant
peripheral nerve sheath tumor” (MPNST) all monomor-
phous, spindle cell sarcomas arising in nerve. Alternative
diagnoses are infrequently considered. Herein, we report
the clinicopathologic features of 10 primary synovial
sarcomas of nerve, all with molecular genetic confirma-
tion of the synovial sarcoma-specific translocation t(X;18)
[16].2. Materials and methods
2.1. Case selection
The consultation archives of 2 of the authors (B. W. S.,
A. L. F.) were searched for cases coded as “synovial
sarcoma” occurring as primary tumors of nerve. All lesions
were limited to nerve; no tumors with features of secondary
neural involvement were included in this study. The tumor
of case 3 was encountered in practice at another institution
by one of the authors (M. A. E.). The diagnosis of synovial
sarcoma was based largely on its characteristic histology,
as well as on clinicopathologic features dissimilar to
MPNST, fully half of which occur in association with
NF1 and arise in transition from neurofibroma, are far more
often high grade (85%), and show far greater histologic
diversity [3]. All tumors were found to be positive for
either the SS18-SSX1 (4 cases) or SS18-SSX2 (6 cases)
gene fusions by reverse transcriptase–polymerase chain
reaction (RT-PCR).
2.2. Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
immunostained for vimentin (Dako, Carpinteria, CA; 1:500,
V9), epithelial membrane antigen (EMA) (Dako, 1:50, E29),
S-100 protein (Dako, 1:1600, polyclonal), CD57 (Becton
Dickinson, 1:20; HNK-1), neurofilament protein (Dako,
1:800, 2F11), collagen IV (Dako, 1:25, CIV22), TLE1
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA; dilution
1:100, polyclonal), Fli1 (BD Pharmingen, San Jose, CA; 1:50,
BRD, G146-254), and Ki-67 (Dako, 1:30, MIB-1) using heat-
induced epitope retrieval and the Dako Envision detection
system. Appropriate positive and negative controls were used.2.3. Molecular genetics
Methods for the characterization of synovial sarcoma
including RT-PCR (10 cases) and fluorescence in situ
hybridization (FISH) (1 case) have been previously pub-
lished elsewhere [17].3. Results3.1. Clinicopathologic features
Essential clinical and therapeutic data regarding our 10
cases are summarized in Table 1. The tumors occurred in 7
female and 3 male patients ranging in age from 11 to 68 years
(mean, 40 years), inclusive of 4 pediatric cases.3.2. Imaging
Imaging was available for review in 4 patients (cases 2, 3,
5, 8). All had MRI examinations (3 with gadolinium
enhancement) performed at 1.5 T or lower. A positron
emission tomography (PET) scan was available in a single
patient (case 2). The nerves involved were the distal tibial
nerve, peroneal division of the sciatic nerve, median nerve
in the distal arm, and the middle trunk of the brachial
plexus. All lesions arose from the affected nerve and
extended proximally and distally along its length (“tail
sign”) (Figs. 1 and 2A). In the case of the tibial nerve lesion
(case 3), the mass extended from the common tibial nerve
into the medial and lateral plantar branches. All lesions were
isointense to muscle on T1-weighted imaging, hyperintense
on T2-weighted sequences, and showed avid enhancement
in the 3 cases wherein post-contrast images were available
(Figs. 1 and 2A). Smaller lesions showed homogeneous
enhancement. The large, complex sciatic lesion (case 2)
showed a more heterogeneous signal and enhancement in
addition to hemorrhage within the largest portion of the
tumor. Of the 4 tumors (cases 1, 2, 3, 8), 3 were oval in
shape and ranged from slightly less than 1 cm to 3 cm in
maximum dimension with irregular margins in each case.
The sciatic lesion (case 2) was multinodular, the 4 distinct,
ovoid nodules collectively measuring 19 cm in length and 4
cm in maximal axial dimension (Fig. 2A). The PET scan in
this case showed avid uptake of the fluorodeoxyglucose
(FDG) in all the nodules (Fig. 2B). On reinterpretation of
imaging, the 4 tumors, based on the presence of irregular
margins, were considered indeterminate in nature and
suspicious for malignancy.3.3. Operative findings
The tumors ranged in size from 1.5 to 19.5 cm (mean,
3.25 cm; median, 10.7 cm). At surgery, all involved the
substance of a nerve, the 4 smaller examples being described
as intraneural (cases 1, 3, 6, 7). In the majority of cases,
operative reports indicated that a clear resection plane was
not evident. Only one small (3.5 × 1.5 × 1.0 cm) tumor
(case 5) was stated to involve a single fascicle seen to both
enter and exit the lesion. With one exception (case 2; Fig. 3),
all tumors were uninodular.
Table 1 Synovial sarcoma of nerve
Present series
Case Age/
sex
Presentation Nerves
involved
Imaging Operative features Tumor
size
Resection
(ST/GT)
Radio-/
chemotherapy
Follow-up
1 47/F Ankle mass Deep peroneal N/A Intraneural, ovoid 2.4 × 1.3 ×
1.0
GT No/yes No recurrence
at 8 y
2 11/M Idiopathic, isolated
right peroneal n.
palsy at age 6 mo.
Painful R posterior
thigh mass at
age 10 y
Sciatic nerve
thigh and common
peroneal nerve
Avid, irregular
enhancement
Irregular margins
Parent nerve seen
FDG PET strongly
positive
Intraneural,
multinodular
19.5 × 5.0
× 4.5 cm
ST; focal
margin
involvement
No/unstated N/A
3 42/M Pain medial to
L ankle × 2 y.
Mass at site recent
Tibial nerve Irregular, localized
enlargement of the
nerve with extension
into the medial and
lateral plantar branches
Intraneural, ovoid,
noninfiltrative
1.5 × 0.8
cm
GT Unstated N/A
4 64/M Sudden onset
L leg weakness
and bladder
incontinence
L4 nerve root Enhancing intraspinal
and foraminal mass
Intra- and
extraspinal
unencapsulated
and hemorrhagic
Tumor 3.0
× 2.0 × 0.4
cm and 1.0
× 1.0 × 0.4)
ST Unstated N/A
5 68/F Pain above L elbow
and numbness
in hand. Previous
failed carpal
tunnel release
Median nerve
distal arm
Avid, irregular
enhancement
Irregular margins
Mildly heterogeneous
T2 signal
Parent nerve seen
Uninodular.
Nerve-attached;
one entering/
exiting fascicle
3.5 × 1.5 ×
1.0 cm
ST No/no Wide resection and
reconstruction 2 mo
after diagnosis; no
recurrence at 4.5 y
6 15/F N/A Brachial plexus
(C7, middle trunk)
N/A Intraneural,
plexiform
5.3 × 0.9 ×
0.9 cm
ST Yes/yes Metastasis to spine
(4 mo postop then
brain; died
1.5 y postop)
7 13/F Painful popliteal
fossa mass
Tibial nerve MRI consistent with
nerve sheath tumor
Uninodular,
encapsulated nerve
fascicles attached
4.5 × 3.5 ×
1.7 cm
GT Unstated N/A
8 52/F Left shoulder,
arm and chest
wall pain × 3 y
Brachial plexus—
middle trunk
Avid, slightly
irregular enhancement
Irregular margin distally
Parent nerve seen
Ovoid, encapsulated
but adherent to
surrounding
fascicles—more
than a single fascicle
2.1 × 1.7 ×
1.9 cm
GT Yes/no No recurrence at
2.5 y postop.
Full body PET
scan negative
9 17/F N/A R peroneal N/A N/A 3.5 × 3 ×
2.5 cm
N/A N/A N/A
10 28/F N/A R ulnar N/A N/A N/A N/A N/A N/A
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Table 1 (continued)
Literature review
Published cases,
author(s)
(reference)
Age/
sex
Presentation Nerve(s) involved Imaging Operative finding Size (cm) Resection
(ST/GT)
Radio-/
chemotherapy
Follow-up
Cugola and
Pisa [7]
16/F Mass and palsy Radial No lesion
on x-ray
Encapsulated
intraneural tumor.
Sural graft
2.0 GT No/no Well at 5 y;
functional recovery
Rinehart
et al [10]
23/F 2 y pain,
palpable mass
Median CT and MRI
showed tumor
Intraepineural tumor 2.5 GT No/no Sural nerve graft;
partial functional
recovery; well at
7 mo
O'Connell
et al [9]
16/M 1 y enlarging
palm “lump”
Radial, common
digital branch
– Intraneural tumor 2.5 GT/ray resection
middle finger
No Unstated
Tacconi
et al [12]
44/F Supraclav mass;
C5-C6 sensory
symptoms
Brachial plexus CT: heterogeneous
mass with
calcifications
Nerve
(perifascicular)
2 × 1.5 cm ST Yes
(55 Gy)/yes
Immediate GT
reexcision.
ChemoRx
Spielmann
et al [11]
43/M 3 wk enlarging,
tender, mass
popliteal fossa;
pain/numbness
in foot, Tinel sign
Tibial nerve,
popliteal fossa
X-ray: delicate
calcifications;
MRI: mass in
tibial nerve
Tumor within
nerve sheath
3.5 Biopsy; AK
amputation.
Tumor in tibial
and common
peroneal nerve
No/no Tumor-free at 8 mo
Chesser
et al [5]
16/M 1 y mass of
flexor R wrist
Median Unstated Tumor within
epineurium
2.0 Unstated Yes/no No recurrence at 1 y
Zenmyo
et al [15]
58/F Sciatica; S1
sensory deficit
S1 root X-ray: calcifications;
CT and MRI: mass
anterior to
S1 foramen
Intraneural tumor
in foramen and
retroperitoneum
5.5 cm ST No/no Dead of pulmonary
adenocarcinoma
at 6 mo
Lestou
et al [8]
54/M Palsy Peroneal n. Thickened nerve Intraneural tumor Unstated Biopsy Unstated Unstated
Chu et al
[6],
case 1
46/F Infra-auricular
mass × several
months
Facial Lemon shape Local excision;
+ margin
0.8 ST and
wide excision
Yes/no No recurrence at 5 y
Chu et al
[6],
case 2
11/F Pain in C and
T distribution;
triceps/biceps
atrophy
C6-C7 MRI: expansile
lesion at foramen
Schwannoma-
like lesion
0.4 GT Postoperative
proton beam/
yes
One recurrence at
1.5 y; re-excision.
Reexcision of tumor
(histologically
biphasic).
Chemotherapy.
Hemiplegia 22 mo
thereafter due to
intraspinal spread
(C4-C6). DOD 6 y
after initial diagnosis
(continued on next page)
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572 B. W. Scheithauer et al.3.4. Pathology
Of the 10 tumors, 9 showed classic histologic features of
monophasic synovial sarcoma, including a fascicular
proliferation of monomorphic, hyperchromatic spindled
cells in association with wiry collagen and a branching,
“staghorn” vascular pattern (Fig. 4). In one instance (case 2),
a biphasic variant, epithelial differentiation, took the form of
small glands lined by cuboidal to slightly columnar cells
(Fig. 5). Mitotic activity ranged from 1 to 13/10 high-
powered fields (HPF) (mean, 4/10 HPF). No tumor showed
calcification. Round cell areas or necrosis, that is, poorly
differentiated histology, was not encountered.
3.5. Immunohistochemical findings
The immunohistochemical results are summarized in
Table 3 and illustrated in Fig. 6. All tumors were diffusely
positive for vimentin. Patchy expression of EMA, pan-
cytokeratin, and cytokeratin 7 was seen in the spindled cells
of 90%, 80%, and 100% of studied cases, respectively. S100
protein and CD57 were positive in a variable number of cells
in 50% and 100% of cases. Immunostains for neurofilament
protein showed single or grouped and aligned axons within 6
of 8 tumors studied (cases 1, 3, 4, 5, 7, 8), suggesting either
intrafascicular origin or extension of the tumor (Fig. 6F).
Diffuse nuclear expression of TLE1 protein was present in all
cases. No case expressed FLI-1 protein.
3.6. Molecular genetic findings
As noted previously, 6 cases were known to carry the
SS18-SSX2 fusion and 4, the SS18-SSX1 fusion.
3.7. Literature review
Comparable data regarding the 12 previously published
cases are summarized in Tables 1 and 2.4. Discussion
Synovial sarcoma is a relatively common malignant soft
tissue neoplasm, comprising approximately 10% of soft
tissue sarcomas. Despite its name, synovial sarcoma rarely
involves synovium or joints. It is now abundantly clear that
this tumor bears no relationship to synovium. Synovial
sarcomas most often involve the extremities of adolescents
and young adults but may occur in patients of any age and in
any soft tissue or even visceral location. Indeed, with the
discovery that synovial sarcomas carry a variety of specific
translocations, including t(X;18)(p11.23;q11)(SS18-SSX1)
(∼65% of cases), t(X;18)(p11.21;q11) (SS18-SSX2) (∼35%
of cases), t(X;18)(p11;q11) (SS18- SSX4) (b1% of cases),
and t(X;20)(p11;q13.3) (SS181-SSX1) (b1% of cases), the
Fig. 1 A, Case 8. Coronal T2-weighted MR image without fat suppression showing a relatively well-marginated mass in the middle trunk of
the supraclavicular brachial plexus (asterisk). The mass is bright on T2 with mild signal heterogeneity. The normal nerve proximal and distal to
the lesion is clearly seen. B, Case 8. Post-contrast T1-weighted image with fat suppression at the same level as A. This image shows the
irregular margins of the tumor, especially at its distal aspect (arrows) and avid contrast enhancement.
Fig. 2 A, Case 2. Sagittal T1-weighted image after gadolinium
enhancement in the thigh shows heterogeneous contrast enhancement
within the nodules of the mass extending along the peroneal division
of the sciatic nerve. The margins are irregular and the most proximal
nodule has nonenhancing areas consistent with necrosis (asterisk). At
least 4 dominant nodules are seen. The nerve proximal to the mass is
seen and is normal. The distal extent of themass is not included on this
image. B, Case 2. Sagittal FDG-PET image of the trunk and thigh
shows avid uptake in the multinodular mass within the thigh.
573Synovial sarcoma of nervediagnostic application of molecular techniques (RT-PCR,
FISH) has made it increasingly apparent that many synovial
sarcomas occur in unusual locations [18,19].
Primary synovial sarcomas of nerve are very rare, there
being only 22 reported cases, inclusive of those in the present
series (Tables 1 and 2) [5-12,14,15]. Extremely rare cases of
intraneural metastases from synovial sarcoma have also been
reported [20]. As noted in the present study, the morphologic
and immunohistochemical features of intraneural synovial
sarcomas are essentially identical to those of their more
common soft tissue counterparts. However, 9 (90%) of 10
cases in the present series were of monophasic type, as
compared with 70% of soft tissue cases, and 6 (60%) of 10
carried SS18-SSX2 fusions, versus the 35% frequency seen
in synovial sarcomas at nonneural sites. This suggests that
synovial sarcomas of nerve have some unique features.
Given the relatively small sample size, however, it is entirely
possible that these findings represent a statistical aberration.
The radiographic features of primary intraneural synovial
sarcoma have not been previously described in depth.
Imaging studies were available for 4 of cases in the present
series. The lesions had similar imaging characteristics: all had
irregular margins and clearly were associated with individual
nerves. None had imaging features suggestive of a benign
nerve sheath tumor. Indeed, 3 of the 4 cases had MR imaging
characteristics consistent with MPNST. One tumor affecting
the tibial nerve (case 7) was not as characteristic, presenting
with less prominent localized enlargement of the nerve, an
appearance indeterminate by imaging criteria; contrast
enhancement, which might have improved sensitivity and
narrowed the differential diagnosis, was unavailable in this
case. The one instance wherein PET imaging was available
(case 2) showed avid uptake of the tracer FDG. Although thisis occasionally seen in cellular, benign nerve sheath tumors,
the appearance in this case was more consistent with a
malignant process. Soft tissue synovial sarcomas are usually
heterogeneously isointense on T1, bright on T2-weighted
Fig. 3 Case 2. Gross photo of the specimen showed this unusual
tumor of the peroneal division of the sciatic nerve to be multilobed.
ig. 4 Case 5. Histologically, most of the lesions were
onophasic, consisting of sheaves of spindle cells associated
ith collagen bundles (original magnification ×400).
Fig. 5 Case 3. A single tumor of the biphasic subtype, featuring
well-formed glands (original magnification ×600).
574 B. W. Scheithauer et al.imaging, and homogeneously enhancing in most cases.
Approximately one third of tumors will have associated
calcifications, a feature lacking in our 4 cases. On imaging,
soft tissue synovial sarcomas are often mistaken for benign
nerve sheath tumors given their oval shape and frequent
longitudinal orientation relative to surrounding soft tissue.
Nonetheless, close inspection shows slight irregularity of
their margins and no association with an individual nerve.
This is in sharp distinction to the cases reviewed herein,
where the parent nerve was always visualized.
The differential diagnosis for primary intraneural synovial
sarcoma is mainly with conventional, spindle cell MPNST.
The morphologic features of monophasic synovial sarcomas
and conventional, spindle cell MPNST are remarkably
similar. The only features offering significant discriminatory
assistance being tumor occurrence in a patient with
documented neurofibromatosis type 1 and/or an origin from
a preexisting plexiform neurofibroma. Additional morphol-
ogies include the presence of wiry collagen and stromal
calcifications in synovial sarcoma and the often greater
pleomorphism of MPNST. Even glandular differentiation
may be seen in both synovial sarcoma and MPNST, although
the glands of biphasic synovial sarcoma tend to be small,
lined by cuboidal cells, and filled with eosinophilic debris, in
contrast to the enteric-type glands seen in those extremelyF
m
wrare MPNST with glandular differentiation [21]. Similarly,
the immunophenotypes of monophasic synovial sarcoma and
MPNST show considerable overlap, with frequent expression
of putative nerve sheath markers such as S100 protein and
CD57 in synovial sarcoma [22], expression of EMA both in
synovial sarcoma and in MPNST with perineurial differen-
tiation, rare reported cytokeratin-positive MPNST [23], and
very focal or even absent expression of epithelial markers in
some monophasic synovial sarcomas. CD34 expression,
frequently present in MPNST, particularly low-grade exam-
ples [24] but essentially unheard of in synovial sarcoma, may
be helpful in this differential diagnosis. TLE1, a WNT
pathway-associated transcription factor, has recently been
shown to be a highly sensitive marker of synovial sarcomas,
typically showing expression in nearly 100% of nuclei in a
given tumor [25]. TLE1 is not, however, a perfectly specific
marker, as it may be positive in a significant number of benign
andmalignant peripheral nerve sheath tumors, albeit typically
Table 2 Synovial sarcoma of nerve: histology, immunohistochemistry, genetics
Present cases
Case Histologic
type
Mitoses/
10 HPF
EMA AE1-AE3 S-100
protein
CD57 TLE-1 Fli1 NFP showing
nerve association
PCR
1 Monophasic 13 + 1+ + 1+ 4+ – Axons SYT-SSX2
2 Monophasic 10 – 1+ – 1+ 2+ – – SYT-SSX1
3 Biphasic 3 2 2+ – 2+ 4+ – Axons SYT-SSX1
4 Monophasic 2 1 2+ 1+ 2+ 3+ – Axons SYT-SSX1
5 Monophasic 4 2 – 1+ 1+ 1+ – – SYT-SSX2
6 Monophasic 3 1+ 1+ – 3+ 4+ – Axons SYT-SSX2
7 Monophasic 2 2+ 1+ 1+ 1+ 4+ – Axons SYT-SSX2
8 Monophasic 3 2+ 1+ ND 3+ 1+ – Axons SYT-SSX2
9 Monophasic 1 1+ 2+/no 1+ ND ND ND Axons SYT-SSX2
10 Monophasic 2 scant 1+/NA 1+ ND 2+ ND – SYT-SSX1
Literature review
Published cases,
author(s) (reference)
Histologic
type
EMA KERATIN S100
protein
NFP showing
nerve association
Miscellaneous Genetics/PCR
Cugola and Pisa [7] Biphasic NA NA NA NA – SYT-SSX1
Rinehart [10] Monophasic Focal+ Focal+ Focal+ Axons Desmin—focal SYT-SSX2
O'Connell [9] Biphasic + b5% 15%-20%+ Neg Axons SMA, CD34- x;18
Tacconi et al [12] Monophasic + + Focal+ NA – NA
Spielmann et al [11] Biphasic Focal Neg Neg Axons CD99+; MSA,
Desmin−
SYT-SSX2
Chesser et al [5] Biphasic NA + NA NA SYT-SSX1
Zenmyo et al [15] Monophasic + + NA NA bcl-2+ t(x;18) (p11;q11)
SYT-SSX - ?later
Lestou et al [8] Monophasic Minor+ Minor+ Minor+ NA Vimentin and
CD99+
Cryptic t(x;18),
ins (6;18)
and SYT-SSX2
gene fusion
Chu et al [6], case 1 Biphasic + Tumor and
perineurium
+ Neg Axons – t(x;18) (SYT-
SSX)
Chu et al [6], case 2 Monophasic Neg Neg Neg
Nerve
fibers+
Axons _ t(x;18) (SYT-
SSX)
Weinreb et al [14] Biphasic + + Neg Neg Desmin, actin,
and CD34−;
BCL-2+
SYT-SSX1
Uehara et al [13] Monophasic + + + + SYT-SSX1
Abbreviations: NFP, neurofilament protein; NA, not assessed; ND, not done.
NOTE. Scant = less than 5%; 1+ = 5% to 25%; 2+ = 25% to 50%; 3+ = more than 50%.
1+ = 1% to 10%; 2+ = 11% to 25%; 3+ = 26% to 50%; 4+ = 51% to 100%.
575Synovial sarcoma of nervein a smaller percentage of tumor nuclei [26]. A large number
of other markers, including BCL-2, SYT protein, CD56,
p75NTR, nestin, and HMGA2 protein, have been suggested
to be of some value in this differential diagnosis but either
lack specificity (BCL-2, CD56) or have been studied only in a
very small number of cases (nestin, HMGA2).
Given some morphologic and considerable immunophe-
notypic overlap between synovial sarcoma and MPNST,
demonstration of one of the synovial sarcoma-associated
fusion genes has come to be regarded as the “gold standard”
for this differential diagnosis. Although it was initially
asserted that MPNST and other types of nerve sheath tumors
could contain the (X;18) translocation [27], this hassubsequently been disproved by a number of large, carefully
performed studies [28-30]. Positive molecular markers of
MPNST, which may also be of value in this differential
diagnosis, includeNF1 and p16 deletions aswell as epidermal
growth factor receptor amplification and polysomies for
either chromosome 7 or 22 as demonstrated by FISH [31].
In conclusion, we have described the clinical, radiographic,
pathologic, and molecular genetic findings in 10 cases of
primary intraneural synovial sarcoma, the largest series to date.
In general, primary intraneural synovial sarcomas are similar to
their more common soft tissue counterparts, although there
may be a relative intraneural predominance of monophasic
tumors and tumors containing SS18-SSX2 fusions. Based on
Fig. 6 The immunophenotype of the tumors included keratin (A; case 3), epithelial membrane antigen (B; case 3), S-100 protein reactivity
(C; case 5), CD57 (D; case 6), and TLE1 (E; case 6). Axons immunoreactive for neurofilament protein were identified within some tumors and
indicated endoneurial involvement (F; case 7) (A-F, original magnification ×400).
576 B. W. Scheithauer et al.relatively limited follow-up, we see no reason to believe that
the behavior of intraneural synovial sarcomas is any different
from that of synovial sarcomas at other locations, particularly
in extremities. Definitive recommendations regarding possible
roles for adjuvant radiation and chemotherapy await the study
of additional cases.The present series, even combined with our literature
review, has limitations with regard to assessing recurrence/
survival data. Nonetheless, several clinicopathologic factors
appear to affect outcome. Comparing our data with that of
Lewis et al [32], a multivariate analysis of prognostic factors
in 112 patients with primary localized synovial sarcomas of
577Synovial sarcoma of nervethe extremities, we believe that small tumor size may affect
the prognosis. Of the combined 22 patients in our report and
review study, 16 (73%) had small (b5 cm) tumors, a
meaningful prognostic factor according to Lewis et al [32].
An early presentation with neurologic symptoms may be the
basis of their small size. Indeed, 15 (75%) of 20 patients
experienced sensorimotor loss and/or pain, a not surprising
presentation for a nerve-based tumor. Thus, synovial
sarcomas of nerve may be associated with a more favorable
prognosis than nonneural examples. Relative to MPNST of
the extremities, particularly lower extremity examples,
which have a poor prognosis [33], synovial sarcomas at
this site appear to have a more favorable prognosis.
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